1-5 of 5 results for subject:Pfizer
Librarians' tools
- Search time
- 0.179 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, what steps he is taking (a) to ensure the provision of Pfizer vaccines to people who cannot take Moderna and (b) with ICBs which have insufficient supplies of the Pfizer vaccine in North Northumberland constituency.
To ask the Secretary of State for Health and Social Care, what steps he is taking (a) to ensure the provision of Pfizer vaccines to people who cannot take Moderna and (b) with ICBs which have insufficient supplies of the Pfizer vaccine in North Northumberland constituency.
The UK Health Security Agency (UKHSA) procures vaccines that have been approved by the Medicines and Healthcare products Regulatory Agency and are advised for use in COVID-19 booster programmes by the Joint Committee on Vaccination and Immunisation (JCVI). The make-up of vaccine availability can vary from campaign to campaign based on the latest JCVI and clinical advice and procured stock available.
Published advice in the COVID-19 Green book, chapter 14a recommends that those with known contraindications to COVID-19 vaccination should seek advice from a relevant specialist. This may include an allergy specialist, who can make a clinical assessment of the individual's risks and benefits of vaccination. If suitable, these individuals may be advised to be vaccinated in hospital under medical supervision.
During the 2025 Spring COVID-19 vaccination campaign, UKHSA did not receive any reports of supply issues in North Northumberland.
Vaccine deployment is managed by NHS England which works with the regional teams and integrated care boards to ensure the vaccine is readily available for those eligible, as per the JCVI advice. UKHSA has worked and continues to work with all deployment partners to ensure the supply and provision of vaccines.
To ask the Secretary of State for Health and Social Care, whether the Pfizer COVID-19 vaccine will be offered by the NHS in the Spring booster programme.
To ask the Secretary of State for Health and Social Care, whether the Pfizer COVID-19 vaccine will be offered by the NHS in the Spring booster programme.
The spring 2025 campaign will continue to use mRNA vaccine supply secured under existing pandemic contracts with Pfizer and Moderna. Those eligible will be offered either Moderna or Pfizer/BioNTech vaccines during the spring 2025 campaign.
To ask the Secretary of State for Health and Social Care, with reference to paragraph 3.19 of the minutes of the Covid-19 Vaccine Benefit Risk Expert Working Group held on 18 November 2020, if he will publish the communications undertaken to inform recipients of the Pfizer/BioNTech mRNA vaccine about its...
To ask the Secretary of State for Health and Social Care, with reference to paragraph 3.19 of the minutes of the Covid-19 Vaccine Benefit Risk Expert Working Group held on 18 November 2020, if he will publish the communications undertaken to inform recipients of the Pfizer/BioNTech mRNA vaccine about its...
The reactogenicity of vaccines refers to their capacity to produce common or “expected” adverse reactions following vaccination such as fever, tiredness, and a sore arm at the vaccination site. These reactions, and the frequency with which they occur, are listed in section four of the vaccine package leaflet, which states what possible side effects people may experience. Regarding the reference to reactogenicity in paragraph 3.19 of the minutes of the COVID-19 Vaccine Benefit Risk Expert Working Group held on 18 November 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) published information for the recipients of the Pfizer/BioNTech mRNA vaccine, as well as for healthcare professionals. These documents detail the reactogenic nature of the vaccines, and are available, respectively, at the following two links:
The MHRA also regularly published coronavirus vaccine summaries of Yellow Card reporting throughout the pandemic. Amongst many other matters regarding the safety of the COVID-19 vaccines, the reactogenic nature of the vaccines was regularly discussed in these communications, which are available at the following link:
Regarding paragraph 3.7 of these same minutes, the MHRA published product information for the COVID-19 vaccines on the GOV.UK website when regulatory approval was given, starting from 2 December 2020 when the Pfizer/BioNTech (Comirnaty) vaccine was the first COVID-19 vaccine in the world to be approved. On this day, the risk-based evaluation for the Pfizer/BioNTech mRNA vaccine referenced in this paragraph of the minutes was published as part of a summary of the public assessment report for the COVID-19 vaccine Pfizer/BioNTech, which is available at the following link:
To ask the Secretary of State for Health and Social Care, with reference to paragraph 3.7 of the minutes of the Covid-19 Vaccine Benefit Risk Expert Working Group held on 18 November 2020, if he will publish the risk-based evaluation for the Pfizer/BioNTech mRNA vaccine.
To ask the Secretary of State for Health and Social Care, with reference to paragraph 3.7 of the minutes of the Covid-19 Vaccine Benefit Risk Expert Working Group held on 18 November 2020, if he will publish the risk-based evaluation for the Pfizer/BioNTech mRNA vaccine.
The reactogenicity of vaccines refers to their capacity to produce common or “expected” adverse reactions following vaccination such as fever, tiredness, and a sore arm at the vaccination site. These reactions, and the frequency with which they occur, are listed in section four of the vaccine package leaflet, which states what possible side effects people may experience. Regarding the reference to reactogenicity in paragraph 3.19 of the minutes of the COVID-19 Vaccine Benefit Risk Expert Working Group held on 18 November 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) published information for the recipients of the Pfizer/BioNTech mRNA vaccine, as well as for healthcare professionals. These documents detail the reactogenic nature of the vaccines, and are available, respectively, at the following two links:
The MHRA also regularly published coronavirus vaccine summaries of Yellow Card reporting throughout the pandemic. Amongst many other matters regarding the safety of the COVID-19 vaccines, the reactogenic nature of the vaccines was regularly discussed in these communications, which are available at the following link:
Regarding paragraph 3.7 of these same minutes, the MHRA published product information for the COVID-19 vaccines on the GOV.UK website when regulatory approval was given, starting from 2 December 2020 when the Pfizer/BioNTech (Comirnaty) vaccine was the first COVID-19 vaccine in the world to be approved. On this day, the risk-based evaluation for the Pfizer/BioNTech mRNA vaccine referenced in this paragraph of the minutes was published as part of a summary of the public assessment report for the COVID-19 vaccine Pfizer/BioNTech, which is available at the following link:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 January 2025 to Question 23741 on Coronavirus: Vaccination, if he will publish (a) the questions posed to Pfizer/BioNTech and (b) the answers received that do not relate to commercially confidential issues.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 January 2025 to Question 23741 on Coronavirus: Vaccination, if he will publish (a) the questions posed to Pfizer/BioNTech and (b) the answers received that do not relate to commercially confidential issues.
The Medicines and Healthcare products Regulatory Agency (MHRA) does not intend to publish these questions, or any subsequent responses received from the manufacturers. It is routine practice for regulatory authorities to ask developers of new medicines and vaccines a series of technical questions based on their data submissions. These technical discussions can cover a range of issues, including commercially confidential issues such as manufacturing methods, and as such they are not published. However, the final outcome of the assessment, including a comprehensive summary of evidence for quality, safety, and efficacy, is published in the form of a Public Assessment Report, which has been published on the GOV.UK website, and which is available at the following link:
We recognise that there is a public interest in the disclosure of commercial information
relating to the authorisations of the COVID-19 vaccines following the COVID-19 pandemic.
Due to the technical context of the 36 questions posed to Pfizer and BioNTech and any response that they may have issued, disclosure of such correspondence would risk compromising an existing competitive market environment, which would harm the reputation of the MHRA amongst pharmaceutical manufacturers and potentially disincentivise them from seeking an authorisation for the United Kingdom for highly beneficial new medicines or medical devices.